tiprankstipranks
Kura Oncology (KURA)
NASDAQ:KURA
US Market
KURA
Kura Oncology
RESEARCH TOOLSreports
Want to see KURA full AI Analyst Report?

Kura Oncology (KURA) Stock News & Sentiment

849 Followers
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
Premium
Ratings
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
17d ago
KURA
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
Premium
Ratings
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
20d ago
KURA
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
21d ago
ANGX
IMRX
Kura Oncology Earnings Call Highlights Comzifty Launch
Premium
Company Announcements
Kura Oncology Earnings Call Highlights Comzifty Launch
2M ago
KURA
Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook
Premium
Ratings
Early Komzifti Traction and Clinical Catalysts Underpin Buy Rating and 2028 Growth Outlook
2M ago
KURA
Kura Oncology: Early KOMZIFTI Launch Momentum, Robust AML Data, and Strong Cash Runway Underpin Buy Rating
Premium
Ratings
Kura Oncology: Early KOMZIFTI Launch Momentum, Robust AML Data, and Strong Cash Runway Underpin Buy Rating
2M ago
KURA
KURA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
KURA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
KURA
More KURA News >

KURA News on the Web

Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
TipRanks News
Bullish
Kura Oncology (KURA) Shows Promising Phase 1 Trial Results for Kidney Cancer Treatment
GuruFocus News
Bullish
Kura Oncology’s Darlifarnib Combo Achieves 44% Response Rate in Difficult-to-Treat RCC—Signals Potential to Overcome Drug Resistance
Market Chameleon
Neutral
Kura Oncology reports results from ongoing FIT-001 clinical trial
TipRanks News
Bullish
Darlifarnib Plus Cabozantinib Shows Strong Response Rates in Heavily Pretreated Renal Cell Carcinoma—44% ORR and 94% DCR Stand Out
Market Chameleon
Neutral
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
TipRanks News
Neutral
Kura Oncology initiated with a Buy at Lake Street
TipRanks News
Neutral
Syndax assumed with a Buy at Jefferies
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
KURA
Sector Average
Media Buzz
This Week7 articles
Weekly Average0.75 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is KURA’s Media Buzz Sentiment?
7 articles about KURA were published this week. In an average week, 0.75 articles are published.
    What is KURA’s weekly average amount of articles?
    In an average week, 0.75 articles about KURA are published.
      What is KURA’s News Sentiment?
      100% of articles about KURA were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week